Midatech Pharma Plc Book/Share
What is the Book/Share of Midatech Pharma Plc?
The Book/Share of Midatech Pharma Plc is 10.09
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with book/share similar to Midatech Pharma Plc
- Dynavax Technologies has Book/Share of 10.06
- Shah Foods has Book/Share of 10.08
- CVB has Book/Share of 10.08
- Union Jack Oil plc has Book/Share of 10.08
- New World Development has Book/Share of 10.09
- First Seacoast Bancorp has Book/Share of 10.09
- Midatech Pharma Plc has Book/Share of 10.09
- PepsiCo has Book/Share of 10.09
- Ceva has Book/Share of 10.09
- Mazda Motor has Book/Share of 10.09
- Lingbao Gold has Book/Share of 10.09
- Companhia Brasileira De Distribuicao has Book/Share of 10.10
- BE Semiconductor Industries NV has Book/Share of 10.10